<h2>About the Webinar</h2>
As influenza and its complications continue to challenge public health systems, new data and insights are shaping the future of flu prevention. During the webinar the latest findings from the FLUNITY-HD study were presented and discussed and their implications for national immunization programs explored.

<h2>About the FLUNITY-HD Study</h2>
The FLUNITY HD study, a pooled analysis of the DANFLU-2 and GALFLU studies, represents the largest ever individually randomized clinical trials in influenza vaccination, collectively studying over 460,000 older adults across Denmark and Spain. These pragmatic studies with registry-based follow-up aim to definitively demonstrate whether high-dose flu vaccines outperform standard-dose vaccines in preventing hospitalizations linked to influenza.

Monday September 15th, 2025 16:00-17:15 CET

GRIEP

VACCINES

FLUNITY-HD: Results of the pooled analysis of the two individually randomized real-world studies, DANFLU 2 and GALFLU

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Efluelda®, (Trivalent influenza vaccine (split virion, inactivated)), suspension for injection in pre-filled syringe, 60 micrograms HA/strain
A/Victoria/4897/2022 (H1N1) pdm09-like strain, A/Croatia/10136RV/2023 (H3N2)-like strain, B/Austria/1359417/2021 -like strain
- Compulsory Information
Presentation: Efluelda contains 60 micrograms of antigen (per 0.5 mL) from each of the three virus strains recommended by the World Health Organization for the present influenza season. It is supplied as a single dose pre-filled syringe containing 0.5 mL of suspension for injection. The vaccine may contain traces of eggs, such as ovalbumin, formaldehyde which are used during the manufacturing process. Indication: Efluelda is indicated for active immunisation in adults 60 years of age and older for the prevention of influenza disease. Efluelda should be used in accordance with official recommendations on vaccination against influenza. Dosage and administration: In adults 60 years of age and older: one dose of 0.5 ml. The preferred route of administration is intramuscular although it may also be given subcutaneously. The recommended site for intramuscular injection is the deltoid region. It should not be injected into the gluteal region, or into areas where there may be a major nerve trunk. The safety and effectiveness of Efluelda in children less than 18 years of age have not been established. Contraindications: Hypersensitivity to the active substances or to any of the excipients or to any component that may be present as traces such as eggs (ovalbumin, chicken proteins) and formaldehyde. Warnings and precautions: In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded. Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic reaction following the administration of the vaccine. Do not administer intravascularly. Vaccination should be postponed in patients with acute febrile illness until the fever is resolved. If Guillain-Barré syndrome (GBS) has occurred within 6 weeks of any previous influenza vaccination, the decision to give Efluelda should be based on careful consideration of the potential benefits and risks. The vaccine should be administered with caution to subjects with thrombocytopaenia or a bleeding disorder since bleeding may occur following an intramuscular administration to these subjects. Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to the needle injection. Procedures should be in place to prevent injury from fainting and manage syncopal reactions. Antibody response in patients with endogenous or iatrogenic immunosuppression may be insufficient. As with any vaccine, a protective response may not be elicited in all vaccine recipients. Efluelda contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially “sodium free”. Interactions: Co-administration of Efluelda Tetra with an investigational booster 100 mcg dose of COVID-19 mRNA vaccine (nucleoside modified/elasomeran) has been evaluated in a limited number of participants in a descriptive clinical study. If Efluelda needs to be given at the same time as another injectable vaccine(s), immunisation should be carried out on separate limbs. Adverse reactions may be intensified by any co-administration. The immunological response may be reduced if the patient is undergoing immunosuppressant treatment. Fertility, pregnancy and lactation: Efluelda is only indicated for use in adults aged 60 years and older. Efluelda has not been clinically evaluated in pregnant and breast-feeding women. Undesirable effects: Very common: Injection site pain, injection site erythema, malaise, myalgia, headache; Common: Injection site swelling, injection site induration, injection site bruising, fever (≥37.5 °C), shivering. For a complete list of undesirable effects please refer to the full Summary of Product Characteristics. Health care professionals are asked to report any suspected adverse reactions via their national reporting system. Marketing authorization holder: Sanofi Winthrop Industrie, 82 Avenue Raspail, 94250 Gentilly. Legal Classification of the medicinal product regarding medical prescription: Prescription Only Medicine. Date of last review: July 2025. 
 Abbreviated Prescribing Information based on the EU SmPC as of July 2025.
Before prescribing the product always refer to your full local prescribing information as this information may vary from country to country.
NETHERLANDS: Prescription status: Prescription only. Date of last update: July 2025. Reimbursement: Reimbursement procedure pending. Local representative: Sanofi B.V., Paasheuvelweg 25, 1105 BP Amsterdam, the Netherlands.
Target audience of invitation: infectologists, virologists, microbiologists, GPs. 
 Purpose of invitation and meeting: scientific meeting, no accreditation points.

Heeft u vragen of wilt u meer weten? Wij zorgen dat u zo snel mogelijk geholpen wordt.

Wij staan klaar

<h2>Een interview met Cardioloog Prof. Dr. Leonard Hofstra en Viroloog prof. Ab Osterhaus</h2>
Griep gaat verder dan alleen griep. Het kan verregaande gevolgen hebben op verschillende orgaansystemen, waaronder het hart. Tijdens het ESH congres in Berlijn werd dit onderwerp in het mini symposium “Influenza: If you had a vaccine to prevent heart attacks!” wederom onder de aandacht gebracht.
We blikken met sprekers cardioloog prof. Dr. Leonard Hofstra en viroloog prof. Ab Osterhaus terug op dit mini symposium. Zij vertellen wat volgens hen de belangrijkste leerpunten waren van dit symposium.

<h3>Interview met Cardioloog Prof. Dr. Leonard Hofstra</h3>

<h3>Interview met Viroloog prof. Ab Osterhaus</h3>

MEER OVER DE GEVOLGEN VAN GRIEP

Key take aways mini symposium “Influenza: If you had a vaccine to prevent heart attacks!” at the ESH congress in Berlin 2024

Voor uw intercontext, meld u aan bij uw account Sanofi Campus. Geef uw e-mail door aan uw e-mail.

Als u onze eerste e-mail op {email} tot bevestig uw account u kunt hieronder een nieuwe aanvragen. Als je het niet ziet, moet je mogelijk je spammap controleren.

Deze informatie wordt alleen gebruikt om uw account te valideren en wordt niet verspreid.

titel

Title

This website is for healthcare professionals only.

Welcome to BP Sanofi Campus

Create new password

Om u een gepersonaliseerde ervaring te bieden, moet u

Je profiel is onvolledig

De ADCT geeft een indicatie van hoe gecontroleerd het eczeem is. Beantwoord deze 6 eenvoudige vragen met uw patiënt om de ADCT-score te vinden. Het zal de juiste handelwijze aangeven.

Atopische dermatitis, een vorm van eczeem, kan het leven van uw patiënt op meer manieren beïnvloeden dan u weet.

Doe de atopische dermatitis controle test (ADCT)

Geniet van meer exclusieve inhoud{newline}door <a>door u vandaag te registreren</a>

Heb je al een account? <a>Hier inloggen</a>

Best practices voor het optimaliseren van de patiëntenzorg

Krijg een aangepast beeld van de onderwerpen waarin u geïnteresseerd bent, samen met de mogelijkheid om inhoud op te slaan om op een later tijdstip te bekijken of te lezen.

Onbeperkte toegang tot eersteklas inhoud, whitepapers, casestudy's, onderzoekspapers, webinars, training en up-to-date wetenschappelijke medische bronnen.

Gepersonaliseerde inhoud op basis van uw interessegebieden

Maak contact en blijf up-to-date met collega's op uw vakgebied en onderwerpen die u interesseren via gratis evenementen en leidinggevende forums.

Registreer om het volledige artikel te lezen.

Wij respecteren uw privacy en zullen uw informatie niet delen met derden.

Actuele gidsen die speciaal voor patiënten zijn geschreven

Onbeperkte toegang tot de nieuwste patiëntengidsen en bronnen. Deel inhoud met uw patiënten met gebruiksvriendelijke online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Beperkte toegang

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

Normaal gesproken bieden we een schat aan kenis, maar we konden niet vinden waar je naar op zoek bent.

We konden niet vinden wat je zocht

Sanofi is niet verantwoordelijk voor de inhoud van deze externe website.

U staat op het punt Campus.sanofi/nl te verlaten.

Images from <a>iStockphoto.com</a>, Fotolia.de, <c>gettyimages.de</c>, <d>pexels.com</d> and <e>photocase.de</e> were used for our websites.

Volg ons:

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus®, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch. All fields are required.

Would you also like to receive future messages and updates about Beyfortus?

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Are you enrolled in CENRIFKI REMS?

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your local Sanofi representative and/or to receive updates about Qfitlia. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required (unless otherwise specified).

All fields are required. (unless otherwise specified)

Sanofi biedt u exclusieve content over onze verschillende therapeutische gebieden op één portal speciaal voor professionals in de gezondheidszorg, inclusief wetenschappelijk nieuws, een lijst met evenementen en tools en diensten voor uw dagelijkse praktijk.

Bevestig uw status

Welcome to ITP Sanofi Campus

De inhoud van deze website is alleen toegankelijk voor geregistreerde gebruikers.

Log in alstublieft

Email verificatie

U ziet een voorbeeld van de portal. Wis uw cookies (bijvoorbeeld door uw browservenster te sluiten) om terug te gaan naar de openbare modus.

We hebben onze privacyverklaring bijgewerkt om je gegevens beter te beschermen en je ervaring te verbeteren. Neem even de tijd om de wijzigingen door te nemen door <privacyNewTab>hier te klikken</privacyNewTab>. Uw privacy is belangrijk voor ons. Klik op doorgaan om te bevestigen dat u de nieuwe privacyverklaring hebt gelezen.

Update van de privacyverklaring

Communicatie toestemming

My consents

Password

Confirm password

{resultsCount, plural, one {resultaat} other {resultaten}}

Log in om toegang te krijgen tot de resultaten

U moet inloggen op uw account om toegang te krijgen tot medische inhoud.

Inloggen

Registreer in minder dan 1 minuut om toegang te krijgen tot de resultaten

U verlaat nu het Sanofi inhoudsgedeelte van onze site en komt in het inhoudsgedeelte voor extern medisch bibliografisch zoeken.

U verlaat nu het externe medische bibliografische zoekgedeelte van onze site en komt in het inhoudsgedeelte van Sanofi.

Griep

Educatie

FLUNITY-HD: Results of the pooled analysis of the two individually randomized real-world studies, DANFLU 2 and GALFLU

Key take aways mini symposium “Influenza: If you had a vaccine to prevent heart attacks!” at the ESH congress in Berlin 2024